Research Analysts’ Recent Ratings Changes for uniQure (QURE)

uniQure (NASDAQ: QURE) has recently received a number of price target changes and ratings updates:

• 6/18/2026 – uniQure had its price target raised by Royal Bank Of Canada from $35.00 to $65.00. They now have an “outperform” rating on the stock.
• 6/18/2026 – uniQure had its “buy” rating reaffirmed by HC Wainwright.
• 6/18/2026 – uniQure had its price target raised by Leerink Partners from $36.00 to $70.00. They now have an “outperform” rating on the stock.
• 6/18/2026 – uniQure had its price target raised by The Goldman Sachs Group, Inc. from $14.00 to $46.00. They now have a “neutral” rating on the stock.
• 6/18/2026 – uniQure was upgraded by Barclays PLC from “equal weight” to “overweight”. They now have a $65.00 price target on the stock, up from $25.00.
• 6/17/2026 – uniQure had its “positive” rating reaffirmed by Barclays PLC.
• 6/17/2026 – uniQure was upgraded by Cantor Fitzgerald from “neutral” to “overweight”. They now have a $61.00 price target on the stock.
• 5/6/2026 – uniQure had its price target lowered by HC Wainwright from $70.00 to $50.00. They now have a “buy” rating on the stock.
• 5/5/2026 – uniQure was given a new $28.00 price target by Stifel Nicolaus.
• 4/30/2026 – uniQure had its price target raised by Chardan Capital from $31.00 to $37.00. They now have a “buy” rating on the stock.

Insider Transactions at uniQure

In other uniQure news, insider Walid Abi-Saab sold 45,000 shares of uniQure stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $25.06, for a total value of $1,127,700.00. Following the transaction, the insider directly owned 169,669 shares of the company’s stock, valued at $4,251,905.14. The trade was a 20.96% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Kylie O’keefe sold 15,936 shares of the business’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $27.06, for a total value of $431,228.16. Following the completion of the sale, the insider owned 108,864 shares of the company’s stock, valued at $2,945,859.84. The trade was a 12.77% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 324,134 shares of company stock valued at $12,778,769. 4.65% of the stock is currently owned by corporate insiders.

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.